Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Pradaxa Label Update May Increase Use Over Warfarin, Despite Risks June 11, 2012 Irvin Jackson Add Your Comments Federal drug regulators are allowing a label update for the controversial anticoagulant Pradaxa, which may increase use of the medication over Coumadin (warfarin), despite hundreds of deaths and thousands of reports involving bleeding problems from Pradaxa over first two years it has been on the market. The new Pradaxa label update was announced by Boehringer Ingelheim on June 6, indicating that new information will be added to the label that suggests Pradaxa is better than warfarin at reducing the risk of ischemic and hemorrhagic strokes. The new label information is based on data from clinical trials known as RE-LY, which were used to obtain FDA approval to market the medication in October 2010. The claims that the drug is superior to warfarin will appear in the Clinical Studies section of the drug’s label. However, the same trial has come under fire from critics, who have suggested that the RE-LY study was fundamentally flawed, and that the medication never should have been approved based on the trials results. Learn More About Pradaxa Internal Bleeding Lawsuit Side effects of Pradaxa may increase risk of severe bleeding and death. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Pradaxa Internal Bleeding Lawsuit Side effects of Pradaxa may increase risk of severe bleeding and death. Learn More SEE IF YOU QUALIFY FOR COMPENSATION According to a letter published last year in the Therapeutics Initiative (PDF), researchers from the University of British Columbia criticized the study, indicating that it allowed bias and errors to creep into the results. While the trial used a double-blind method of comparison between the two doses of Pradaxa, a non-blinded comparison was used between Pradaxa and warfarin. Pradaxa (dabigitran) was introduced as the first alternative to Coumadin (warfarin) for the prevention of stroke among patients with atrial fibrillation. However, the drug quickly earned a darker reputation after it became associated with reports of uncontrolled hemorrhaging and bleeding deaths. While bleeding problems that develop with use of Coumadin can be reversed through a dose of Vitamin K, which can be given to patients to stop the drug’s anticoagulation effects, no such reversal agent is available for Pradaxa users. Therefore, doctors are often left unable to stop bleeding, often resulting in serious injury or death. The new Pradaxa label update was announced just days after a report by the Institute for Safe Medication Practices (ISMP) found that problems with Pradaxa topped the FDA’s list for most adverse event reports in 2011. The ISMP quarterly MedWatch report found that among adverse event reports submitted to the FDA last year, Pradaxa was identified as the cause for 542 patient deaths in the United States and more cases of severe hemorrhage than any other medication, including warfarin. Boehringer Ingelheim faces a growing number of lawsuits over Pradaxa brought on behalf of individuals who suffered serious or fatal injuries due to uncontrollable bleeding while taking the medication. According to allegations raised in the complaint, the drug maker recklessly promoted the medication as superior to warfarin without adequately warning consumers or the medical community about the lack of reversal agent or risk of serious bleeding events. Tags: Blood Thinner, Blood Thinners, Boehringer Ingelheim, Coumadin, Pradaxa, Stroke, Warfarin More Pradaxa Lawsuit Stories Jury Awards $540K in Pradaxa Trial Against Boehringer Ingelheim May 21, 2019 Paragard IUD Lawsuit Dismissed on Summary Judgment February 25, 2019 Boehringer Ingelheim Ordered to Pay $1.25M For Failure to Warn About Pradaxa Bleeding Risks October 25, 2018 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermCommentsThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: today) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025) Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor (Posted: yesterday) As new Depo-Provera lawsuits continue to be filed, the judge presiding over the litigation has established key criteria for establishing proof of Depo-Provera use and medical documentation confirming a meningioma diagnosis. MORE ABOUT: DEPO-PROVERA LAWSUITDepo Shot Lawsuit Filed Over Serious Brain Tumor Injuries (05/07/2025)Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (05/01/2025)Depo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025) BioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (Posted: 2 days ago) A Massachusetts woman’s injuries from a failed tissue marker that was recently recalled led to the need for physical therapy, according to a BioZorb implant lawsuit. MORE ABOUT: BIOZORB LAWSUITFour Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025)Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (04/02/2025)
Boehringer Ingelheim Ordered to Pay $1.25M For Failure to Warn About Pradaxa Bleeding Risks October 25, 2018
MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: today) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)
Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor (Posted: yesterday) As new Depo-Provera lawsuits continue to be filed, the judge presiding over the litigation has established key criteria for establishing proof of Depo-Provera use and medical documentation confirming a meningioma diagnosis. MORE ABOUT: DEPO-PROVERA LAWSUITDepo Shot Lawsuit Filed Over Serious Brain Tumor Injuries (05/07/2025)Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (05/01/2025)Depo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025)
BioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (Posted: 2 days ago) A Massachusetts woman’s injuries from a failed tissue marker that was recently recalled led to the need for physical therapy, according to a BioZorb implant lawsuit. MORE ABOUT: BIOZORB LAWSUITFour Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025)Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (04/02/2025)